You are here

VRTX

$151.26

-0.53%

Investor Relations

News & Events

Filter Releases
 
Press Releases
Date Title and Summary View
Sep 19, 2017
-Eleven abstracts from Vertex's CF program accepted for presentation- -Late-breaking abstract submitted with data from three different triple combination regimens in CF patients- BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today annou...
Sep 6, 2017
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Tom Graney to the role of Senior Vice President and Chief Financial Officer (CFO). Mr. Graney will begin his role with Vertex on September 13, 2017 and will report to Executive Vice President and Chief ...
Aug 24, 2017
-FDA grants Priority Review of the application and sets action date of February 28, 2018- -Applications supported by positive results from two global Phase 3 studies in people with CF ages 12 and older who have two copies of the F508del mutation or one F508del mutation and one residual function ...
Aug 1, 2017
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved KALYDECO® (ivacaftor) for use in more than 600 people with cystic fibrosis (CF) ages 2 and older who have one of five residual function mutations...
Jul 25, 2017
BOSTON & LEXINGTON, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the completion of their previously announced asset purchase agreement. Under the completed agreement, Vertex now has worldwide development and ...
Jul 18, 2017
-Phase 2 data showed mean absolute improvements in ppFEV1 of 9.7 and 12.0 percentage points for VX-152 and VX-440, respectively, in triple combination with tezacaftor and ivacaftor in F508del/Min patients; Initial data from Phase 1 study showed mean absolute improvement in ppFEV1 of 9.6 percentage points ...
Jul 17, 2017
Boston Public High School Students Hannah Mei and Sayed Shah Receive Vertex Science Leaders Scholarship to Pursue STEM Degrees at UMass BOSTON--(BUSINESS WIRE)-- Vertex, Boston Public Schools (BPS) and the University of Massachusetts today announced the recipients of the an...
Jul 13, 2017
- Effective immediately, agreement enables hundreds of people in Italy to access this important medicine - - Recent pricing and reimbursement agreements have enabled broad access to ORKAMBI for thousands of eligible patients in multiple European countries; negotiations continue in a number of othe...
Jun 9, 2017
- Presentation of data from a Phase 3 study of ORKAMBI in children ages 6-11 with two copies of the F508del mutation demonstrated improvements in lung function and sweat chloride; study also published online in The Lancet Respiratory Medicine today - - ECFS data presentations demonstrate that trea...
Jun 8, 2017
BOSTON--(BUSINESS WIRE)-- Shareholders of Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today elected Alan M. Garber, M.D., Ph.D. as an independent member of its board of directors. Dr. Garber is Provost of Harvard University, the Mallinckrodt Professor of Health Care Policy at Harvard Medical Schoo...
Jun 1, 2017
-Agreement provides access to ORKAMBI for people who have two copies of the F508del mutation and expands access to KALYDECO for all eligible patients- LONDON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) today announced it has reached an agreement wit...
May 19, 2017
- New Program Helps CF Families Pursue Higher Education - BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the first recipients of the company's All in for CF Scholarship program. Each of the 40 scholarship recipients will be awarded $5,00...
May 17, 2017
- Precision medicine decision based on in vitro data and supported by more than five years of real-world clinical data that demonstrate KALYDECO's strong safety and efficacy profile for eligible patients - - Vertex working with FDA to obtain rapid approval for more than 600 additional people who h...
May 4, 2017
Third Annual CF "Circle of Care" Grants Connect CF Community Members Around the World to Share Their Ideas and Inspiration BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the grant recipients for its 2017 Cystic Fibrosis (CF) Circl...
Jan 8, 2017
-Full-year 2016 product revenues of approximately $703 million for KALYDECO and $979 million for ORKAMBI; total 2016 CF product revenues of $1.68 billion compared to $983 million in 2015- -Company provides 2017 financial guidance for KALYDECO product revenues of $690 to $710 million and ORKAMBI pr...
Jan 10, 2016
-Approximately 25,000 people with cystic fibrosis worldwide currently eligible for treatment with ORKAMBI® (lumacaftor/ivacaftor) or KALYDECO® (ivacaftor); Vertex advancing the development of multiple medicines with the goal of treating all people with cystic fibrosis- -Fourth q...
Nov 23, 2015
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the appointment of Michael J. Parini to the role of Executive Vice President and Chief Legal Officer. Mr. Parini will serve as a member of Vertex's Executive Committee, reporting directly to Jeffrey Leiden, M.D.,...
Aug 19, 2015
Hosts August 19th back to school event with Bottom Line for 200+ first-generation college students BOSTON--(BUSINESS WIRE)-- Vertex and the University of Massachusetts (UMass) today announced the recipients of the annual Vertex Science Leaders Scholarship, a four-y...
Jun 18, 2015
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Sangeeta N. Bhatia, M.D., Ph.D., joined its board of directors as an independent director. Dr. Bhatia was elected to serve a three-year term ending in 2018. "Dr. Bhatia is a leading ...
Jan 11, 2015
-Priority Review granted for combination of lumacaftor and ivacaftor in people with cystic fibrosis ages 12 and older who have two copies of the F508del mutation; PDUFA date of July 5, 2015- -More than 3,700 people with CF expected to be eligible to receive KALYDECO by end of 2015 supporting conti...
Dec 15, 2014
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated today announced that David Altshuler, M.D., Ph.D., will join the company as Executive Vice President, Global Research and Chief Scientific Officer. Dr. Altshuler was one of the four founding members of the Broad Institute of Harvard University...
Jul 10, 2014
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Peter Mueller, Ph.D., Executive Vice President of Global Research and Development and Chief Scientific Officer, will retire after more than 10 years with the company. Dr. Mueller's retirement will be effecti...
May 7, 2014
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that William Young joined its board of directors as an independent director. Mr. Young was elected to the class of directors whose term expires in 2017. The Vertex board now consists of 10 members. ...
Jan 12, 2014
-KALYDECO: 2014 revenue growth anticipated from geographic expansion and approval for use in patients with additional CFTR mutations- -Lumacaftor in combination with ivacaftor: results from two Phase 3 studies, TRAFFIC and TRANSPORT, expected mid-year in people with two copies of the F508...
Jan 8, 2014
BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Jeffrey A. Chodakewitz, M.D., as Chief Medical Officer and Senior Vice President. Dr. Chodakewitz has more than 20 years of experience leading global development organizations in the b...
Jun 18, 2013
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has completed its previously announced call for redemption of $400 million in aggregate principal amount of 3.35% Convertible Senior Subordinated Notes due 2015. Holders of $400 million in aggre...
May 17, 2013
-2015 Notes convertible at a conversion price of approximately $48.83 per share- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that it has called for redemption of its outstanding $400.0 million in aggregate principal amoun...
Apr 5, 2013
-Two Phase 2 studies to evaluate once-daily combination of Vertex's investigational nucleotide analogue VX-135 and BMS' investigational NS5A replication complex inhibitor daclatasvir- -Study in people with genotype 1 hepatitis C planned to begin in second quarter of 2013- ...
Jan 6, 2013
-2013 investment focused on key development programs in cystic fibrosis, hepatitis C and autoimmune diseases- -First two Breakthrough Therapy Designations from U.S. FDA granted to ivacaftor monotherapy and to the combination regimen of VX-809 and ivacaftor for the treatment of cystic fibrosis- ...
Nov 10, 2012
- New Phase 2 data showed approximately 3 of 4 people co-infected with hepatitis C virus (HCV) and HIV achieved HCV viral cure (SVR24) with telaprevir combination treatment - BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that new data f...
Sep 18, 2012
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Yuchun Lee joined its board of directors as an independent director. Mr. Lee was appointed to the class of directors whose term expires in 2013. The Vertex board currently consists of 10 members. ...
Sep 4, 2012
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Stuart A. Arbuckle as Executive Vice President and Chief Commercial Officer. Mr. Arbuckle has more than 25 years of experience in leading global sales and marketing efforts at biophar...
Jun 18, 2012
-Vertex commits more than $1 million to support education for BPS students and to prepare teachers for new science education standards- -Company dedicates 3,000 square foot learning laboratory at new Fan Pier headquarters to local community- BOSTON--(BUSINESS WIRE)-- ...
Jun 8, 2012
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced two changes to its executive leadership team. Following a comprehensive search, Vertex has appointed Kenneth Horton to the role of Chief Legal Officer, where he will take on the additional title of Exec...
May 24, 2012
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that David Altshuler, M.D., Ph.D., joined its board of directors as an independent director. Dr. Altshuler was appointed to the class of directors whose term expires in 2015. With the addition of Dr. ...
Jan 8, 2012
-More than 25,000 people have started treatment for hepatitis C with INCIVEK®, positioning Vertex for continued growth, earnings and cashflow in 2012- -Preparations for approval and launch of KALYDECOTM ongoing; additional studies of KALYDECO planned for mid-2012- -Ni...
Dec 15, 2011
-Jeffrey Leiden, M.D., Ph.D., to become CEO in February 2012- -Matthew Emmens elects to retire in May; will remain director for Vertex Board- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that its Board of Dire...
Sep 15, 2011
-Vertex hiring for 150 jobs across the company to support global growth; Company plans to add more than 500 jobs through 2015- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Science has ranked the company #1 in the magazine's annua...
May 17, 2011
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Terrence C. Kearney has joined its board of directors. The addition of Mr. Kearney brings the number of Vertex board members to nine. Mr. Kearney was appointed to the class of directors whose term ...
May 12, 2011
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2011 Annual Meeting of Shareholders. At the meeting, shareholders re-elected director nominees Matthew W. Emmens and Wayne J. Riley, M.D. and elected nominee Margaret...
Apr 28, 2011
-Advisory Committee for the Food and Drug Administration reviewing the telaprevir New Drug Application for the treatment of hepatitis C- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) announced that NASDAQ today halted trading of the company's common s...
Jan 9, 2011
-Hepatitis C: Submission of New Drug Application complete for telaprevir- -Cystic Fibrosis: First Phase 3 data for VX-770 expected in first quarter 2011- -Additional ongoing trials in HCV, CF, epilepsy and rheumatoid arthritis- -Vertex enters 2011 ...
Sep 24, 2010
CAMBRIDGE, Mass., Sep 24, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriter for its offering of 3.35% convertible senior subordinated notes due 2015 has exercised in full its option to purchase an additional $25 million aggregate principal amount of notes. The ...
Sep 23, 2010
CAMBRIDGE, Mass., Sep 23, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into an agreement to sell $375.0 million aggregate principal amount of 3.35% convertible senior subordinated notes due 2015. Vertex has granted the underwriter an option to purchase up to a...
Sep 22, 2010
CAMBRIDGE, Mass., Sep 22, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that intends to offer, subject to market and other conditions, $375.0 million aggregate principal amount of convertible senior subordinated notes due 2015 in an underwritten public offering under an automatica...
Jul 13, 2010
CAMBRIDGE, Mass., Jul 13, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Wayne J. Riley, M.D., M.B.A., joined its board of directors as an independent director. The addition of Dr. Riley brings the number of Vertex board members to 10. Dr. Riley was appointed to the cl...
May 13, 2010
CAMBRIDGE, Mass., May 13, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2010 Annual Meeting of Shareholders. At the meeting, shareholders re-elected director nominees Dr. Joshua Boger, Dr. Charles A. Sanders and Elaine S. Ullian. Their terms will ...
Feb 16, 2010
CAMBRIDGE, Mass., Feb 16, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that on March 19, 2010 it will redeem the outstanding $32.1 million aggregate principal amount of 4.75% Convertible Senior Subordinated Notes due 2013, in accordance with the terms of the indenture governing those ...
Jan 10, 2010
SAN FRANCISCO, Jan 10, 2010 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs...